ReviewMedComm2025
Current Bioinformatics Tools in Precision Oncology.
Review in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Research progress on biomarkers of blast lung injury: Transition from traditional indicators to novel molecular markers.iScience · 2026Review
- Do papers tell the whole story? A benchmark and framework for uncovering hidden implementation gaps in bioinformatics.Briefings in bioinformatics · 2026Article
- Exploratory Multi-Platform Bioinformatic Analysis of MEAK7 and Its Molecular, Survival, and Immune Associations in Pancreatic Ductal Adenocarcinoma.International journal of molecular sciences · 2026Article
- Review
- Comprehensive overview of AI methodologies in nano-drug delivery Optimization and Design.NPJ precision oncology · 2026Review
- Transcriptomic and epigenomic insights into ovarian cancer: a bioinformatics perspective - a narrative review.Annals of medicine and surgery (2012) · 2026Article
- Pan-cancer analysis identifies KANSL2 as a cell-cycle-associated regulator of tumor progression and immunity in liver hepatocellular carcinoma.Clinical and experimental medicine · 2026Article
- Atranorin suppresses the LUCAT1/STAT3 axis to induce ferroptotic cell death in ovarian cancer.Molecular biology reports · 2026Article
- Functional Depth Biomarkers Distinguish Lung Squamous Cell Carcinoma from Lung Adenocarcinoma.Research square · 2026Article
- Emerging molecular targets in gynaecologic cancers: clinical implications for personalized therapy.Molecular biology reports · 2026Review
- Novel approaches to modulate CAR-T cell function by targeting the tumor microenvironment in ovarian cancer.Journal of ovarian research · 2026Review
- CRISPR/Cas9 in Cancer Therapy: Precision Genome Editing Approaches Targeting Hematological Malignancies and Solid Tumors Through Cellular, Biochemical, and Molecular Mechanisms.Cell biochemistry and biophysics · 2026Review
- Ubiquitin-specific proteases in ovarian cancer: molecular mechanisms and therapeutic implications.Journal of ovarian research · 2026Review
- Multidimensional single-cell analysis of the molecular characteristics and functional pathways of Regulatory T cells in the microenvironment of HR+ breast cancer.Discover oncology · 2026Article
- A novel 'Blended Pedagogy' for integrating bioinformatics into the undergraduate medical curriculum: a pilot study on feasibility and student engagement.BMC medical education · 2026Article
- Beyond Feature Selection: Interpretable Machine Learning for Mechanistic Insights in Metabolomics.Biology · 2026Review
- Metabolic plasticity in pancreatic ductal adenocarcinoma progression and response to treatment.Molecular cancer · 2026Review
- Article
- Conserved Pathways, Divergent Outcomes: A Cross-Species Genomic Perspective on the Cancer-Neurodegeneration Paradox.International journal of molecular sciences · 2026Review
- Early Cancer Detection: What's Going on and What's Next.MedComm · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Integrating bioinformatics tools has profoundly transformed precision oncology by identifying essential molecular targets for personalized treatment. The rapid development of high-throughput sequencing and multiomics technologies creates complex datasets that require robust computational methods to extract meaningful insights. Nonetheless, the clinical application of multiomics data continues to pose significant challenges. This review explores advanced bioinformatics tools utilized within multiomics, emphasizing their pivotal role in discovering cancer biomarkers. Cloud-based platforms, such as Galaxy and DNAnexus, facilitate streamlined data processing, while single-cell analysis software, including Seurat, identifies rare cellular subpopulations. Further integration of artificial intelligence with machine learning approaches improves predictive modeling and diagnostic accuracy. Spatial omics technologies correlate molecular signatures within tumor microenvironments, guiding treatment strategies. Bioinformatics integrates these technologies to establish a new standard in precision oncology, thereby enhancing therapy efficacy. Collaborative initiatives between The Cancer Genome Atlas and cBioPortal expedite advancements through the sharing open data and implementing standardized methodologies. Advancing multiomics integration techniques alongside improved computational capabilities is essential for discovering new biomarkers and refining precision medicine strategies. Future efforts should focus on merging multiomics techniques with innovative computational methods to drive novel biomarker discovery and improve precision medicine applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.